STOCK TITAN
  1. Home
  2. News
  3. CDTX

Cidara Therapeutics Inc - CDTX STOCK NEWS

Welcome to our dedicated news page for Cidara Therapeutics (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cidara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cidara Therapeutics's position in the market.

News
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Cidara Therapeutics to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
Rhea-AI Summary
Janssen Pharmaceuticals has elected to proceed with CD388, an influenza prevention drug being developed by Cidara Therapeutics. Cidara will receive a $7 million milestone payment and could potentially earn $685 million in milestones and royalties. CD388 has shown promising interim efficacy and safety data in Phase 1 and 2a trials, with a single dose decreasing viral replication and lowering influenza incidence rate compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.1%
Tags
none
-
News
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
Rhea-AI Summary
Cidara Therapeutics appoints Dr. Nicole Davarpanah as Senior VP of Translational Research & Development. She will lead the company's oncology efforts and focus on the strategy for developing drug candidates. Dr. Davarpanah brings expertise in immuno-oncology drug development and corporate development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
management
News
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) reported financial results for Q2 2023, with a focus on the progress of its Cloudbreak platform, including Fast Track designation for CD388 in collaboration with Janssen Pharmaceuticals, and ongoing preclinical studies for CD421. Recent corporate highlights include REZZAYO™ commercialization by Melinta, update on the CD388 influenza program, and FDA granting Fast Track designation to CD388. Cidara also joined the Russell Microcap® Index and presented at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit. Financially, revenue increased to $7.6 million for Q2 2023, with cash and cash equivalents totaling $50.4 million. Research and development expenses were $17.1 million, and general and administrative expenses were $3.3 million. Net loss for Q2 2023 was $12.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
earnings
-
News
Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
Rhea-AI Summary
Cidara Therapeutics announces the commercial launch of REZZAYO™ (rezafungin for injection) by its U.S. partner, Melinta Therapeutics. The European Medicines Agency (EMA) is currently reviewing the marketing authorization application (MAA) for rezafungin, with a decision expected by year-end 2023. The total potential transaction value of the Melinta License Agreement is $460.0 million, including upfront and milestone payments. Cidara retains the rights to rezafungin in Japan and is evaluating potential commercial partnerships in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
none
-
News
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
News
Cidara Therapeutics Added to Russell Microcap® Index
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
News
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
clinical trial
-
News
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
News
Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
Rhea-AI Summary
Cidara Therapeutics will present highlights from its ongoing preclinical studies of CD421 and the development of its novel drug-Fc conjugates at the Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
Stock CDTX logo
Cidara Therapeutics Inc

Nasdaq:CDTX

CDTX Rankings

#4764 Ranked by Market Cap
#734 Ranked by Stock Gains
N/A Ranked by Dividends

CDTX Stock Data

73.40M
76.81M
7.53%
30.63%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About CDTX

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.